Nouveaux Medical

Nouveaux is a clinical-stage medical aesthetics company focused on developing next-generation botulinum toxin products. The company's lead candidate, NOU-001, is a premium botulinum toxin type A currently advancing into pivotal clinical trials for the treatment of glabellar lines. Led by a management team with deep expertise from industry leaders like Allergan and Evolus, Nouveaux aims to disrupt the neurotoxin market through scientific innovation and a provider-centric commercial model. In June 2024, the company announced a $130 million Series A financing round to fund the completion of its clinical programs and support its path toward regulatory approval and commercialization.